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Dr Hirochika Ryuno, Department of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
For contribution of 'Differences in the association between high blood pressure and cognitive functioning among the general Japanese population aged 70 and 80 years: The SONIC study. ' Vol. 39, No. 7, http://www.nature.com/hr/journal/v39/n7/full/hr201625a.html This cross-sectional survey analyzed the association of cognitive function with blood pressure and other factors in subjects aged 70 and 80. Systolic blood pressure was a significant factor for cognitive decline in both ages, however, the contribution was less in 80-year-old subjects than in 70-year-old subjects.
HYPERTENSION RESEARCH AWARD Dr Toshiaki Ohkuma, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
For contribution of 'Effects of smoking and its cessation on creatinine-and cystatin C-based estimated glomerular filtration rates and albuminuria in male patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry.' Vol. 39, No. 10, pp 744-751.
http://www.nature.com/hr/journal/v39/n10/full/hr201651a.html The authors indicated the relations of smoking to renal parameters such as albuminuria and estimated glomerular filtration rate in type 2 diabetic patients entered into the registry study, which are expected to facilitate smoking cessation in terms of prevent renal injuries.
HYPERTENSION RESEARCH AWARD Dr Yui Takeshige, Division of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan.
For contribution of 'A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. ' Vol. 39, No. 6, http://www.nature.com/hr/journal/v39/n6/full/hr20162a.html This animal study showed that the administration of SGLT2 inhibitor improves the non-dipper pattern of circadian blood pressure changes in obese rats given high-salt diet. This may be involved in the mechanism by which SGLT2 inhibitors reduce cardiovascular and renal events in clinical trials.
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